{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:49:16Z","timestamp":1782452956357,"version":"3.54.5"},"reference-count":211,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the RNA-dependent RNA polymerase (RdRp) complex is a therapeutic target for influenza, evidence on the pharmacology, resistance, and clinical impact of RdRp-targeting inhibitors in high-risk populations remains fragmented. This scoping review on RdRp-targeting inhibitors identifies the research gaps and characterizes their mechanisms of action, pharmacokinetics, efficacy, safety, and resistance patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Following the \u201cPreferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews\u201d guidelines, a comprehensive search for studies was conducted across PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, Wanfang, and\n                      <jats:uri>ClinicalTrials.gov<\/jats:uri>\n                      from inception to October 2025. Preclinical and clinical studies on influenza RdRp-targeting inhibitors were included, with data charted across eight domains.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 1,282 identified records (English: 1197; Chinese: 85), 156 articles were included. PA inhibitors emerged as the most extensively documented class. Preclinical findings demonstrated potent antiviral activity of PA inhibitors and emerging PB1\/PB2 analogs, with variability in pharmacokinetic profiles. Clinical evidence showed PA inhibitors consistently shorten the time to symptom relief and accelerate viral RNA clearance compared with standard therapy. RdRp-targeting inhibitors showed an acceptable tolerability profile. Resistance was a notable challenge, primarily involving PA-I38 substitutions. Evidence on drug\u2013drug interactions was limited to early-phase trials. A significant evidence gap remains for high-risk populations; baloxavir being the only agent widely studied in high-risk adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RdRp-targeting antivirals represent a promising frontier for influenza treatment, with PA inhibitors being the most extensively validated class. While PB1 and PB2 inhibitors diversify the therapeutic pipeline, their development is hindered by the need for multiple-dose regimens and the emergence of drug resistance. Future research should prioritize inhibitor designs that minimize resistance, as well as combination regimens, to accelerate clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1860682","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:44:46Z","timestamp":1782452686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A scoping review of influenza RdRp-targeting inhibitors: mechanisms, clinical translation, and emerging challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoya","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wei","sequence":"additional","affiliation":[{"name":"Research Laboratory of Clinical Virology, Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erzhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Shanghai Institute of Aviation Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Department of Emergency, Ruijin Hospital Taicang","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"104807","DOI":"10.1016\/j.antiviral.2020.104807","article-title":"Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice","volume":"179","author":"Abed","year":"2020","journal-title":"Antivir. Res."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/DHPS.S470868","article-title":"Baloxavir resistance markers in Influenza a and B viruses in the Americas","volume":"16","author":"Acocal-Ju\u00e1rez","year":"2024","journal-title":"Drug Healthc Patient Saf"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/jac\/dkaa393","article-title":"Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection","volume":"76","author":"Ando","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.3390\/v14092074","article-title":"Genetic evolution of avian Influenza a (H9N2) viruses isolated from domestic poultry in Uganda reveals evidence of mammalian host adaptation, increased virulence and reduced sensitivity to Baloxavir","volume":"14","author":"Atim","year":"2022","journal-title":"Viruses"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/irv.12721","article-title":"Carryover effects of baloxavir acid in human nasopharyngeal\/pharyngeal swabs on infectious titer testing of influenza virus","volume":"14","author":"Baba","year":"2020","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in Influenza a H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/v10110610","article-title":"Combination therapy with oseltamivir and favipiravir delays mortality but does not prevent oseltamivir resistance in immunodeficient mice infected with pandemic a(H1N1) Influenza Virus","volume":"10","author":"Baz","year":"2018","journal-title":"Viruses"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1165\/rcmb.2018-0247TR","article-title":"How the respiratory epithelium senses and reacts to Influenza Virus","volume":"60","author":"Benam","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1128\/jvi.72.7.5493-5501.1998","article-title":"Influenza Virus nucleoprotein interacts with Influenza Virus polymerase proteins","volume":"72","author":"Biswas","year":"1998","journal-title":"J. Virol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"116737","DOI":"10.1016\/j.ejmech.2024.116737","article-title":"Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization","volume":"277","author":"Bonomini","year":"","journal-title":"Eur. J. Med. Chem."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00018-025-05611-1","article-title":"Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches","volume":"82","author":"Bonomini","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"105980","DOI":"10.1016\/j.antiviral.2024.105980","article-title":"Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo","volume":"230","author":"Bonomini","year":"","journal-title":"Antivir. Res."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.antiviral.2013.08.023","article-title":"Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance","volume":"100","author":"Burnham","year":"2013","journal-title":"Antivir. Res."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the Influenza Virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref15","author":"Cagas","year":"2022"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1428095","DOI":"10.3389\/fmicb.2024.1428095","article-title":"Real-world effectiveness and safety of Baloxavir Marboxil or oseltamivir in outpatients with uncomplicated influenza a: an ambispective, observational, multi-center study","volume":"15","author":"Cai","year":"2024","journal-title":"Front. Microbiol."},{"key":"ref17","volume-title":"Antiviral drug resistance among Influenza viruses. Influenza (Flu)","year":"2024"},{"key":"ref18","volume-title":"Influenza antiviral medications: summary for clinicians. Influenza (Flu)","year":"2025"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3390\/v12101139","article-title":"In vitro combinations of Baloxavir acid and other inhibitors against seasonal influenza a viruses","volume":"12","author":"Checkmahomed","year":"2020","journal-title":"Viruses"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"22039","DOI":"10.1021\/acs.jmedchem.4c01979","article-title":"Discovery of novel thiophene-based Baloxavir derivatives as potent cap-dependent endonuclease inhibitors for Influenza treatment","volume":"67","author":"Chen","year":"","journal-title":"J. Med. Chem."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/ph16030365","article-title":"Preclinical study of ZSP1273, a potent antiviral inhibitor of cap binding to the PB2 subunit of Influenza a polymerase","volume":"16","author":"Chen","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"116922","DOI":"10.1016\/j.ejmech.2024.116922","article-title":"Synthesis and anti-influenza virus activity of substituted dibenzoxepine-based baloxavir derivatives","volume":"280","author":"Chen","year":"","journal-title":"Eur. J. Med. Chem."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/infdis\/jiz472","article-title":"Replicative fitness of seasonal influenza a viruses with decreased susceptibility to Baloxavir","volume":"221","author":"Chesnokov","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1038\/ncomms5794","article-title":"Generation and characterization of influenza a viruses with altered polymerase fidelity","volume":"5","author":"Cheung","year":"2014","journal-title":"Nat. Commun."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.antiviral.2021.105092","article-title":"Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: a Japanese multicenter study in the 2019\u20132020 influenza season","volume":"192","author":"Chong","year":"2021","journal-title":"Antivir. Res."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref27","volume-title":"Study of GP681 Tablets Compared with Placebo in Patients with influenza at high risk of influenza Complications","year":"2024"},{"key":"ref28","volume-title":"Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with influenza (ZX-7101A-207)","year":""},{"key":"ref29","volume-title":"Study to Assess the Safety and Efficacy of ZX-7101A in children aged 5\u201311 Years with influenza (ZX-7101A-210)","year":""},{"key":"ref30","volume-title":"Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for oral Suspension","year":""},{"key":"ref31","volume-title":"Enrollment Completed in Phase 2a Study with Cocrystal Pharma\u2019s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza","year":"2024"},{"key":"ref32","volume-title":"Influenza Viral Challenge Study of CC-42344 in Healthy Participants","year":"2025"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/S0735-1097(22)02623-7","article-title":"Baloxavir marboxil for the treatment of influenza virus infection in patients with cardiovascular disease: a subgroup analysis of capstone-2","volume":"79","author":"Collins","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1743-422X-11-167","article-title":"Emerging antiviral resistant strains of influenza a and the potential therapeutic targets within the viral ribonucleoprotein (vRNP) complex","volume":"11","author":"Davis","year":"2014","journal-title":"Virol. J."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza a viruses","volume":"5","author":"De Clercq","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/ph18030297","article-title":"Prodrug approach as a strategy to enhance drug permeability","volume":"18","author":"de Souza","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/bcp.13733","article-title":"Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza a virus polymerase complex, and interaction with oseltamivir: a phase 1 open-label study in healthy volunteers","volume":"84","author":"Deleu","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e1002830","DOI":"10.1371\/journal.ppat.1002830","article-title":"Structural and biochemical basis for development of Influenza Virus inhibitors targeting the PA endonuclease","volume":"8","author":"DuBois","year":"2012","journal-title":"PLoS Pathog."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/ph15010028","article-title":"Baloxavir marboxil: an original new drug against influenza","volume":"15","author":"Dufrasne","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.58347\/tml.2024.1717a","article-title":"Antiviral drugs for seasonal influenza for 2024-2025","volume":"66","year":"2024","journal-title":"Med. Lett. Drugs Ther."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"106174","DOI":"10.1016\/j.antiviral.2025.106174","article-title":"Influenza a(H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: insights from human airway epithelia and murine models","volume":"239","author":"Fage","year":"2025","journal-title":"Antivir. Res."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.02.005","article-title":"Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice","volume":"545","author":"Fang","year":"2020","journal-title":"Virology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b study of Pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza a: TOPAZ trial","volume":"219","author":"Finberg","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.resinv.2020.05.002","article-title":"A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus a with baloxavir marboxil","volume":"58","author":"Fujita","year":"2020","journal-title":"Respir. Investig."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e0217307","DOI":"10.1371\/journal.pone.0217307","article-title":"Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models","volume":"14","author":"Fukao","year":"","journal-title":"PLoS One"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/jac\/dky462","article-title":"Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza a virus infection","volume":"74","author":"Fukao","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antivir. Res."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e01217","DOI":"10.1128\/JVI.01217-18","article-title":"Determining the mutation Bias of favipiravir in Influenza Virus using next-generation sequencing","volume":"93","author":"Goldhill","year":"2019","journal-title":"J. Virol."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e1008937","DOI":"10.1371\/journal.ppat.1008937","article-title":"Favipiravir-resistant influenza a virus shows potential for transmission","volume":"17","author":"Goldhill","year":"2021","journal-title":"PLoS Pathog."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"105853","DOI":"10.1016\/j.antiviral.2024.105853","article-title":"Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for a(H3N2) influenza: a multicenter study of the 2022\u20132023 season","volume":"224","author":"Goto","year":"2024","journal-title":"Antivir. Res."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/molecules26041007","article-title":"Structural and thermodynamic analysis of the resistance development to Pimodivir (VX-787), the clinical inhibitor of cap binding to PB2 subunit of Influenza a polymerase","volume":"26","author":"Gregor","year":"2021","journal-title":"Molecules"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/infdis\/jiz245","article-title":"Baloxavir and treatment-emergent resistance: public health insights and next steps","volume":"221","author":"Gubareva","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1800666","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3390\/v16091467","article-title":"The synergistic effect of Baloxavir and neuraminidase inhibitors against Influenza viruses in vitro","volume":"16","author":"Guo","year":"2024","journal-title":"Viruses"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e017271","DOI":"10.1136\/bmjgh-2024-017271","article-title":"Seasonal influenza surveillance and vaccination policies in the WHO south-east Asian region","volume":"10","author":"Haider","year":"2025","journal-title":"BMJ Glob. Health"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"611958","DOI":"10.3389\/fmicb.2021.611958","article-title":"Improved in vitro efficacy of Baloxavir Marboxil against Influenza a Virus infection by combination treatment with the MEK inhibitor ATR-002","volume":"12","author":"Hamza","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1505557","DOI":"10.3389\/fphar.2024.1505557","article-title":"Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism","volume":"15","author":"Han","year":"2024","journal-title":"Front. Pharmacol."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2174\/1573406414666180112102225","article-title":"Synthesis of a novel class of 1,3-oxathiolane nucleoside derivatives of T- 705 and evaluation of their anti-influenza a Virus and anti-HIV activity","volume":"14","author":"Han","year":"2018","journal-title":"Med. Chem."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/jamainternmed.2023.0699","article-title":"Evaluation of oseltamivir used to prevent hospitalization in outpatients with influenza: a systematic review and meta-analysis","volume":"184","author":"Hanula","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/pds.5392","article-title":"Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: a retrospective cohort study using an employment-based health insurance claims database in Japan","volume":"31","author":"Hara","year":"2022","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1093\/infdis\/jiad409","article-title":"Oral favipiravir exposure and pharmacodynamic effects in adult outpatients with acute Influenza","volume":"230","author":"Hayden","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","article-title":"Favipiravir treatment of uncomplicated Influenza in adults: results of two phase 3, randomized, double-blind, placebo-controlled trials","volume":"226","author":"Hayden","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"109109","DOI":"10.1016\/j.bioorg.2025.109109","article-title":"Discovery of a spirocyclic influenza RNA-dependent RNA polymerase inhibitor","volume":"166","author":"He","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","article-title":"Baloxavir: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"e0000922","DOI":"10.1128\/aac.00009-22","article-title":"Pleiotropic effects of influenza H1, H3, and B baloxavir-resistant substitutions on replication, sensitivity to baloxavir, and interferon expression","volume":"66","author":"Hickerson","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.apsb.2021.11.018","article-title":"Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins","volume":"12","author":"Hou","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/13543784.2021.1994944","article-title":"Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza a virus: a phase 1 double-blind study in healthy subjects","volume":"30","author":"Hu","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir marboxil for prophylaxis against influenza in household contacts","volume":"383","author":"Ikematsu","year":"","journal-title":"N. Engl. J. Med."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jiac.2019.12.002","article-title":"Duration of fever and PA\/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season","volume":"26","author":"Ikematsu","year":"","journal-title":"J. Infect. Chemother."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.chom.2017.09.008","article-title":"A highly pathogenic avian H7N9 Influenza Virus isolated from a human is lethal in some ferrets infected via respiratory droplets","volume":"22","author":"Imai","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"154624","DOI":"10.1016\/j.metabol.2020.154624","article-title":"Outcomes of influenza with treatment in patients with diabetes: subgroup analysis of the phase 3 CAPSTONE-2 trial","volume":"116","author":"Ison","year":"2021","journal-title":"Metabolism"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/nature08260","article-title":"In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses","volume":"460","author":"Itoh","year":"2009","journal-title":"Nature"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e0295424","DOI":"10.1128\/spectrum.02954-24","article-title":"Clinical efficacy of baloxavir marboxil versus oseltamivir in kidney transplant recipients with influenza","volume":"13","author":"Jiang","year":"2025","journal-title":"Microbiol. Spectrum"},{"key":"ref79","volume-title":"MasurasavirTablets Instructions","year":"2025"},{"key":"ref80","volume-title":"A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled, Clinical Efficacy and Safety Study of GP681 Tablets for Post-Exposure Prophylaxis against Influenza in Adults and Adolescents","year":"2024"},{"key":"ref81","volume-title":"A Phase III, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate Pharmacokinetics, Safety and Efficacy of ADC189 Tablets\/Granules in Children 2\u201311 Years Old With Influenza","year":"2024"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","article-title":"The Ambiguous Base-pairing and high substrate efficiency of T-705 (favipiravir) Ribofuranosyl 5\u2032-triphosphate towards Influenza a Virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"ref83","volume-title":"The efficacy and safety of a cap-dependent endonuclease inhibitor, TG-1000, in adolescent and adult outpatients with acute uncomplicated influenza: a multicenter, randomized, placebo-controlled phase III trial","author":"Jin","year":"2024"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/jac\/dkaa527","article-title":"Multiple polymerase acidic (PA) I38X substitutions in influenza a(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibition","volume":"76","author":"Jones","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"105369","DOI":"10.1016\/j.antiviral.2022.105369","article-title":"Influenza a virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir","volume":"204","author":"Jones","year":"2022","journal-title":"Antivir. Res."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40261-018-0697-2","article-title":"Evaluation of drug-drug interaction potential between Baloxavir Marboxil and oseltamivir in healthy subjects","volume":"38","author":"Kawaguchi","year":"","journal-title":"Clin. Drug Investig."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1093\/ofid\/ofy209.115","article-title":"1645. Exploring clinical and antiviral efficacy of baloxavir marboxil in a phase 3, randomized, double-blind, placebo- and active-controlled study of otherwise healthy adults\/adolescents in seasonal influenza: impact on regional participants, treatment time and influenza type B virus infection (CAPSTONE-1 study)","volume":"5","author":"Kawaguchi","year":"","journal-title":"Open Forum Infect. Dis."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1093\/ofid\/ofw172.1786","article-title":"A phase 1 study of safety, tolerability and pharmacokinetics of oral single-dose S-033188, a novel anti-influenza agent, in healthy adult male subjects","volume":"3","author":"Kawasaki","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cts.13160","article-title":"Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects","volume":"15","author":"Kim","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/infdis\/jix606","article-title":"Combination therapy with neuraminidase and polymerase inhibitors in nude mice infected with Influenza Virus","volume":"217","author":"Kiso","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza a viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3390\/v11111066","article-title":"Treatment of highly pathogenic H7N9 Virus-infected mice with Baloxavir Marboxil","volume":"11","author":"Kiso","year":"2019","journal-title":"Viruses"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s42003-020-0952-y","article-title":"Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice","volume":"3","author":"Kiso","year":"","journal-title":"Commun Biol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1093\/jac\/dkad145","article-title":"Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors","volume":"78","author":"Kiso","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/infdis\/jiz665","article-title":"Baloxavir Marboxil treatment of nude mice infected with Influenza a Virus","volume":"221","author":"Kiso","year":"","journal-title":"J. Infect. Dis."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/irv.12760","article-title":"The antiviral effects of baloxavir marboxil against influenza a virus infection in ferrets","volume":"14","author":"Kitano","year":"2020","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF01718315","article-title":"Influenza virus PB1 protein is the minimal and essential subunit of RNA polymerase","volume":"141","author":"Kobayashi","year":"1996","journal-title":"Arch. Virol."},{"key":"ref98","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1021\/acs.biochem.3c00536","article-title":"Structural studies of inhibitors with clinically relevant Influenza endonuclease variants","volume":"63","author":"Kohlbrand","year":"2024","journal-title":"Biochemistry"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"105387","DOI":"10.1016\/j.antiviral.2022.105387","article-title":"Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus a\/PR\/8\/34 (H1N1) using site-directed mutagenesis","volume":"205","author":"Komeno","year":"2022","journal-title":"Antivir. Res."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"16","DOI":"10.32607\/actanaturae.11652","article-title":"Favipiravir and its structural analogs: antiviral activity and synthesis methods","volume":"14","author":"Konstantinova","year":"2022","journal-title":"Acta Nat."},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40261-018-0710-9","article-title":"Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent Baloxavir Marboxil in healthy adults: phase I study findings","volume":"38","author":"Koshimichi","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"e00119-20","DOI":"10.1128\/AAC.00119-20","article-title":"Population pharmacokinetics and exposure-response relationships of baloxavir marboxil in influenza patients at high risk of complications","volume":"64","author":"Koshimichi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/nar\/gkaa1294","article-title":"Structural insights into the substrate specificity of the endonuclease activity of the influenza virus cap-snatching mechanism","volume":"49","author":"Kumar","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref104","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1473-3099(21)00469-2","article-title":"Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial","volume":"22","author":"Kumar","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref105","doi-asserted-by":"publisher","first-page":"e00040-22","DOI":"10.1128\/cmr.00040-22","article-title":"Antiviral approaches against influenza virus","volume":"36","author":"Kumari","year":"2025","journal-title":"Clin. Microbiol. Rev."},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/v15051154","article-title":"In vivo antiviral activity of Baloxavir against PA\/I38T-substituted Influenza a viruses at clinically relevant doses","volume":"15","author":"Kuroda","year":"2023","journal-title":"Viruses"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/infdis\/jiv288","article-title":"E119D neuraminidase mutation conferring pan-resistance to neuraminidase inhibitors in an a(H1N1)pdm09 isolate from a stem-cell transplant recipient","volume":"212","author":"L\u2019Huillier","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref108","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/QCO.0000000000000498","article-title":"Neuraminidase inhibitor resistance in influenza: a clinical perspective","volume":"31","author":"Lee","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref109","doi-asserted-by":"publisher","first-page":"e1008395","DOI":"10.1371\/journal.ppat.1008395","article-title":"Baloxavir treatment of ferrets infected with influenza a(H1N1)pdm09 virus reduces onward transmission","volume":"16","author":"Lee","year":"2020","journal-title":"PLoS Pathog."},{"key":"ref110","doi-asserted-by":"publisher","first-page":"e1009527","DOI":"10.1371\/journal.ppat.1009527","article-title":"Evaluating the fitness of PA\/I38T-substituted influenza a viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model","volume":"17","author":"Lee","year":"2021","journal-title":"PLoS Pathog."},{"key":"ref111","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1093\/infdis\/jiae408","article-title":"Efficacy and safety of Pimodivir combined with standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and adults with Influenza a infection","volume":"231","author":"Leopold","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref112","doi-asserted-by":"publisher","first-page":"S227","DOI":"10.1093\/infdis\/jiaf126","article-title":"New developments in Influenza polymerase inhibitors","volume":"232","author":"Li","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref113","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/jcph.6134","article-title":"Single-dose tolerability and pharmacokinetics of Onradivir in Chinese patients with hepatic impairment and healthy matched controls","volume":"65","author":"Li","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"ref114","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12879-023-08140-z","article-title":"Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013\/2014-2019\/2020 seasons in Japan: an observational study","volume":"23","author":"Li","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"ref115","doi-asserted-by":"publisher","first-page":"e0046225","DOI":"10.1128\/aac.00462-25","article-title":"Pharmacokinetics, safety, and tolerability of onradivir in participants with severe renal impairment and matched healthy control participants","volume":"69","author":"Li","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref116","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.apsb.2025.11.033","article-title":"Anti-influenza drugs targeting trimeric RNA polymerase complex: from development to clinics","volume":"16","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1292735","DOI":"10.3389\/fmicb.2023.1292735","article-title":"Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China","volume":"14","author":"Liao","year":"2023","journal-title":"Front. Microbiol."},{"key":"ref118","doi-asserted-by":"publisher","first-page":"199371","DOI":"10.1016\/j.virusres.2024.199371","article-title":"Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro","volume":"345","author":"Liu","year":"2024","journal-title":"Virus Res."},{"key":"ref119","doi-asserted-by":"publisher","first-page":"e2119151","DOI":"10.1001\/jamanetworkopen.2021.19151","article-title":"Comparison of antiviral agents for seasonal Influenza outcomes in healthy adults and children: a systematic review and network Meta-analysis","volume":"4","author":"Liu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/cts.13237","article-title":"Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals","volume":"15","author":"Liu","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref121","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.virs.2023.06.002","article-title":"PA-E18G substitution in influenza a virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor","volume":"38","author":"Luo","year":"2023","journal-title":"Virol. Sin."},{"key":"ref122","doi-asserted-by":"publisher","first-page":"26742","DOI":"10.1038\/srep26742","article-title":"Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic Influenza a(H5N1) Virus infection in mice","volume":"6","author":"Marathe","year":"2016","journal-title":"Sci. Rep."},{"key":"ref123","volume-title":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Favipiravir in Adult Patients With Uncomplicated Influenza","year":"2015"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3201\/eid1504.081280","article-title":"Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007\u201308 season","volume":"15","author":"Meijer","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref125","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3201\/eid2510.190607","article-title":"Susceptibility of influenza a, B, C, and D viruses to baloxavir1","volume":"25","author":"Mishin","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref126","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/cid\/ciac068","article-title":"Comparison of intra-familial transmission of Influenza Virus from index patients treated with Baloxavir Marboxil or oseltamivir using an Influenza transmission model and a health insurance claims database","volume":"75","author":"Miyazawa","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref127","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1056\/NEJMoa2413156","article-title":"Efficacy of Baloxavir treatment in preventing transmission of Influenza","volume":"392","author":"Monto","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref128","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/molecules26040880","article-title":"Influenza viruses: harnessing the crucial role of the M2 Ion-Channel and neuraminidase toward inhibitor design","volume":"26","author":"Mtambo","year":"2021","journal-title":"Molecules"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"105657","DOI":"10.1016\/j.antiviral.2023.105657","article-title":"The combined effect of oseltamivir and favipiravir on influenza a virus evolution in patients hospitalized with severe influenza","volume":"216","author":"Mu","year":"2023","journal-title":"Antivir. Res."},{"key":"ref130","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1124\/mol.113.087247","article-title":"Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)","volume":"84","author":"Naesens","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref131","volume-title":"Sebaloxavir Marboxil Tablets Instructions","year":"2025"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"69","DOI":"10.31688\/ABMU.2025.60.1.07","article-title":"Suspected adverse drug reactions to favipiravir: insights from EudraVigilance reports","volume":"60","author":"Negru","year":"2025","journal-title":"Arch. Balkan Med. Union"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir. Res."},{"key":"ref134","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/IDR.S389263","article-title":"Preparing for the next Influenza season: monitoring the emergence and spread of antiviral resistance","volume":"16","author":"Oh","year":"2023","journal-title":"Infect Drug Resist"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref136","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1093\/gbe\/evx138","article-title":"The combined effect of oseltamivir and favipiravir on influenza a virus evolution","volume":"9","author":"Ormond","year":"2017","journal-title":"Genome Biol. Evol."},{"key":"ref137","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/infdis\/jiad021","article-title":"A Multicenter, controlled human infection study of Influenza a(H1N1)pdm09 in healthy adults","volume":"228","author":"Ortiz","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref138","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10822-019-00189-w","article-title":"AZT acts as an anti-influenza nucleotide triphosphate targeting the catalytic site of a\/PR\/8\/34\/H1N1 RNA dependent RNA polymerase","volume":"33","author":"Pagadala","year":"2019","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref139","doi-asserted-by":"publisher","first-page":"e0172924","DOI":"10.1128\/aac.01729-24","article-title":"A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects","volume":"69","author":"Pang","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref140","doi-asserted-by":"publisher","first-page":"105126","DOI":"10.1016\/j.antiviral.2021.105126","article-title":"Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza a virus PA gene in a mouse model","volume":"193","author":"Park","year":"2021","journal-title":"Antivir. Res."},{"key":"ref141","doi-asserted-by":"publisher","first-page":"e101325","DOI":"10.1371\/journal.pone.0101325","article-title":"Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic Influenza a(H1N1) infection in mice","volume":"9","author":"Park","year":"2014","journal-title":"PLoS One"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"e0113721","DOI":"10.1128\/AAC.01137-21","article-title":"Baloxavir treatment delays influenza B virus transmission in ferrets and results in limited generation of drug-resistant variants","volume":"65","author":"Pascua","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref143","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/jac\/dky560","article-title":"Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model","volume":"74","author":"Pascua","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref144","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.virusres.2017.01.013","article-title":"Structural insights into RNA synthesis by the influenza virus transcription-replication machine","volume":"234","author":"Pflug","year":"2017","journal-title":"Virus Res."},{"key":"ref145","doi-asserted-by":"publisher","first-page":"1339368","DOI":"10.3389\/fmed.2024.1339368","article-title":"Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza a","volume":"11","author":"Qiu","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s11030-023-10659-x","article-title":"A novel compound to overcome influenza drug resistance in endonuclease inhibitors","volume":"28","author":"Ren","year":"2024","journal-title":"Mol. Divers."},{"key":"ref147","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.2648","article-title":"A pharmacokinetics-time to alleviation of symptoms model to support extrapolation of Baloxavir Marboxil clinical efficacy in different ethnic groups with Influenza a or B","volume":"112","author":"Retout","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref148","doi-asserted-by":"publisher","first-page":"e14249","DOI":"10.1111\/tid.14249","article-title":"Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients","volume":"26","author":"Ringer","year":"2024","journal-title":"Transpl. Infect. Dis."},{"key":"ref149","doi-asserted-by":"publisher","first-page":"105388","DOI":"10.1016\/j.bioorg.2021.105388","article-title":"Exploration of the 2,3-dihydroisoindole pharmacophore for inhibition of the influenza virus PA endonuclease","volume":"116","author":"Rogolino","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref150","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/pathogens11091048","article-title":"Generation and characterization of drug-resistant Influenza B viruses selected in vitro with Baloxavir acid","volume":"11","author":"Saim-Mamoun","year":"2022","journal-title":"Pathogens"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"104951","DOI":"10.1016\/j.antiviral.2020.104951","article-title":"Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018\u20132019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions","volume":"183","author":"Saito","year":"2020","journal-title":"Antivir. Res."},{"key":"ref152","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase","volume":"57","author":"Sangawa","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref153","doi-asserted-by":"publisher","first-page":"S925","DOI":"10.1093\/ofid\/ofz360.2323","article-title":"2645. Clinical outcomes of oseltamivir vs. baloxavir in patients hospitalized with influenza a","volume":"6","author":"Shah","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref154","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/jac\/dkaa252","article-title":"Clinical outcomes of baloxavir versus oseltamivir in patients hospitalized with influenza a","volume":"75","author":"Shah","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref155","volume-title":"A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza","year":"2019"},{"key":"ref156","volume-title":"Medicine for Treating Influenza Comprising a Combination of Cap-Dependent Endonuclease Inhibitor with Anti-Influenza Drug","author":"Shishido","year":"2017"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian Influenza a (H5N1) Virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref158","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1128\/AAC.01739-09","article-title":"In vitro antiviral activity of favipiravir (T-705) against drug-resistant Influenza and 2009 a(H1N1) viruses","volume":"54","author":"Sleeman","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref159","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/jac\/dkp274","article-title":"Intracellular metabolism of favipiravir (T-705) in uninfected and influenza a (H5N1) virus-infected cells","volume":"64","author":"Smee","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref160","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of favipiravir (T-705) and oseltamivir on influenza a virus infections in mice","volume":"54","author":"Smee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref161","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2217\/fvl.13.98","article-title":"Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant Influenza a Virus infections in mice","volume":"8","author":"Smee","year":"2013","journal-title":"Future Virol."},{"key":"ref162","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/s42003-022-04005-4","article-title":"Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model","volume":"5","author":"Stannard","year":"2022","journal-title":"Commun Biol"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The Influenza Virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design","volume":"36","author":"Stevaert","year":"2016","journal-title":"Med. Res. Rev."},{"key":"ref164","doi-asserted-by":"publisher","first-page":"e01825","DOI":"10.1128\/AAC.01825-20","article-title":"Efficacy of a cap-dependent endonuclease inhibitor and neuraminidase inhibitors against H7N9 highly pathogenic avian Influenza Virus causing severe viral Pneumonia in Cynomolgus macaques","volume":"65","author":"Suzuki","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref165","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/095632020301400502","article-title":"In vitro and in vivo activities of T-705 and oseltamivir against influenza virus","volume":"14","author":"Takahashi","year":"2003","journal-title":"Antivir. Chem. Chemother."},{"key":"ref166","doi-asserted-by":"publisher","first-page":"a038687","DOI":"10.1101\/cshperspect.a038687","article-title":"Influenza polymerase inhibitors: mechanisms of action and resistance","volume":"11","author":"Takashita","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref167","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir","volume":"132","author":"Takashita","year":"2016","journal-title":"Antivir. Res."},{"key":"ref168","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/pathogens9090725","article-title":"In vitro characterization of multidrug-resistant Influenza a(H1N1)pdm09 viruses carrying a dual neuraminidase mutation isolated from immunocompromised patients","volume":"9","author":"Takashita","year":"2020","journal-title":"Pathogens"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.3389\/fmicb.2018.03026","article-title":"Susceptibility of Influenza viruses to the novel cap-dependent endonuclease inhibitor Baloxavir Marboxil","volume":"9","author":"Takashita","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref170","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/v15010244","article-title":"Antiviral susceptibilities of distinct lineages of influenza C and D viruses","volume":"15","author":"Takashita","year":"2023","journal-title":"Viruses"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"106173","DOI":"10.1016\/j.antiviral.2025.106173","article-title":"Impact of the polymerase acidic protein E199K substitution in influenza a viruses on baloxavir susceptibility","volume":"239","author":"Takashita","year":"2025","journal-title":"Antivir. Res."},{"key":"ref172","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5582\/ddt.2021.01053","article-title":"Association between anaphylaxis and anti-influenza drug use: an analysis of the Japanese adverse drug event report database","volume":"15","author":"Tanaka","year":"2021","journal-title":"Drug Discov. Ther."},{"key":"ref173","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1038\/s41598-019-39683-4","article-title":"Inhibition of avian-origin influenza a(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil","volume":"9","author":"Taniguchi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref174","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00705-023-05958-5","article-title":"The impact of PA\/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza a viruses to baloxavir","volume":"169","author":"Taniguchi","year":"2024","journal-title":"Arch. Virol."},{"key":"ref175","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of favipiravir and peramivir for the treatment of pandemic influenza a\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antivir. Res."},{"key":"ref176","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00705-013-1922-1","article-title":"In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza a (H1N1) virus","volume":"159","author":"Tarbet","year":"2014","journal-title":"Arch. Virol."},{"key":"ref177","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrmicro.2016.87","article-title":"Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis","volume":"14","author":"te Velthuis","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref178","doi-asserted-by":"publisher","first-page":"100486","DOI":"10.1016\/j.jbc.2021.100486","article-title":"The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor","volume":"296","author":"Todd","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref179","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3851\/IMP3212","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live Influenza Virus: a phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref180","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref181","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/14740338.2025.2495854","article-title":"Comparative safety analysis of baloxavir marboxil and oseltamivir based on the FAERS database","volume":"25","author":"Tu","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"ref182","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/v12121407","article-title":"Evaluation of Baloxavir Marboxil and peramivir for the treatment of high pathogenicity avian Influenza in chickens","volume":"12","author":"Twabela","year":"2020","journal-title":"Viruses"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/infdis\/jiz244","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","volume":"221","author":"Uehara","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref184","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40780-020-00178-4","article-title":"Efficacy of baloxavir marboxil on household transmission of influenza infection","volume":"6","author":"Umemura","year":"2020","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref185","volume-title":"Xofluza (Baloxavir) Prescribing Information","year":"2024"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis","volume":"60","author":"Vanderlinden","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref187","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with Influenza Virus infection","volume":"221","author":"Wang","year":"","journal-title":"J. Infect. Dis."},{"key":"ref188","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cmi.2024.10.020","article-title":"Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2\/3 trial","volume":"31","author":"Wang","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref189","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cmi.2025.01.025","article-title":"Efficacy and safety of single-dose suraxavir marboxil tablet in the treatment of acute uncomplicated influenza in adults: a multi-Centre, randomized, double-blind, placebo-controlled phase 2 clinical trial","volume":"31","author":"Wang","year":"","journal-title":"Clin. Microbiol. Infect."},{"key":"ref190","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41591-024-03419-3","article-title":"Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial","volume":"31","author":"Wang","year":"","journal-title":"Nat. Med."},{"key":"ref191","doi-asserted-by":"publisher","first-page":"106652","DOI":"10.1016\/j.bpc.2021.106652","article-title":"The mechanism of action of T-705 as a unique delayed chain terminator on influenza viral polymerase transcription","volume":"277","author":"Wang","year":"2021","journal-title":"Biophys. Chem."},{"key":"ref192","doi-asserted-by":"publisher","first-page":"103125","DOI":"10.1016\/j.ebiom.2020.103125","article-title":"Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza","volume":"62","author":"Wang","year":"","journal-title":"EBioMedicine"},{"key":"ref193","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2019.01.012","article-title":"Baloxavir marboxil in Japanese patients with seasonal influenza: dose response and virus type\/subtype outcomes from a randomized phase 2 study","volume":"163","author":"Watanabe","year":"2019","journal-title":"Antivir. Res."},{"key":"ref194","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/jcph.2161","article-title":"Potential drug interaction between favipiravir and warfarin in patients with COVID-19: a real-world observational study","volume":"63","author":"Wattana","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"ref195","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11684-024-1115-1","article-title":"Inhibition of cap-dependent endonuclease in influenza virus with ADC189: a pre-clinical analysis and phase I trial","volume":"19","author":"Wei","year":"2025","journal-title":"Front. Med."},{"key":"ref196","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jama.295.8.jed60009","article-title":"Adamantane resistance in influenza A","volume":"295","author":"Weinstock","year":"2006","journal-title":"JAMA"},{"key":"ref197","volume-title":"Clinical practice guidelines for influenza","year":""},{"key":"ref198","volume-title":"Influenza (seasonal)","year":""},{"key":"ref199","volume-title":"The Burden of Influenza","year":""},{"key":"ref200","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3389\/fphar.2025.1722747","article-title":"Effect of itraconazole on pharmacokinetics of ZX-7101A tablets in healthy Chinese subjects","volume":"16","author":"Wu","year":"","journal-title":"Front. Pharmacol."},{"key":"ref201","doi-asserted-by":"publisher","first-page":"107381","DOI":"10.1016\/j.ijantimicag.2024.107381","article-title":"Safety, tolerability, and pharmacokinetics of a novel anti-influenza agent ZX-7101A tablets in healthy chinese participants: a first-in-human phase I clinical study","volume":"65","author":"Wu","year":"","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"1272466","DOI":"10.3389\/fphar.2023.1272466","article-title":"Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref203","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1473-3099(23)00743-0","article-title":"Safety and efficacy of onradivir in adults with acute uncomplicated influenza a infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"24","author":"Yang","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref204","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S2213-2600(25)00046-3","article-title":"Efficacy and safety of onradivir in adults with acute uncomplicated influenza a infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref205","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2169\/internalmedicine.4117-19","article-title":"The comparison of the efficacy of Baloxavir and neuraminidase inhibitors for patients with Influenza a in clinical practice","volume":"59","author":"Yoshii","year":"2020","journal-title":"Intern. Med."},{"key":"ref206","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s10096-020-03888-7","article-title":"Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza a in Yokohama, Japan","volume":"39","author":"Yoshimura","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref207","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2147\/IJGM.S273266","article-title":"Clinical efficacy of Baloxavir Marboxil in the treatment of seasonal Influenza in adult patients: a prospective observational study","volume":"13","author":"Yoshino","year":"2020","journal-title":"Int J Gen Med"},{"key":"ref208","doi-asserted-by":"publisher","first-page":"17464","DOI":"10.1038\/s41598-019-53945-1","article-title":"Molecular dynamics simulation reveals the mechanism by which the Influenza cap-dependent endonuclease acquires resistance against Baloxavir marboxil","volume":"9","author":"Yoshino","year":"2019","journal-title":"Sci. Rep."},{"key":"ref209","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2014.80","article-title":"Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution","volume":"3","author":"Zhang","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"ref210","doi-asserted-by":"publisher","first-page":"106472","DOI":"10.1016\/j.jinf.2025.106472","article-title":"Oral ADC189 for adults and adolescents with uncomplicated influenza","volume":"90","author":"Zhao","year":"2025","journal-title":"J. Infect."},{"key":"ref211","doi-asserted-by":"publisher","first-page":"e0308998","DOI":"10.1371\/journal.pone.0308998","article-title":"Adverse events associated with oseltamivir and baloxavir marboxil in against influenza virus therapy: a pharmacovigilance study using the FAERS database","volume":"19","author":"Zhou","year":"2024","journal-title":"PLoS One"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1860682\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:44:52Z","timestamp":1782452692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1860682\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":211,"alternative-id":["10.3389\/fmicb.2026.1860682"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1860682","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1860682"}}